Induced Pluripotent Stem Cells: Global Markets
Report Highlights
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Report Includes
- 28 data tables and 56 additional tables
- An analysis of the global market for induced pluripotent stem cells (iPSCs) or artificial stem cells
- Analyses of global market trends, with market revenue data from 2020 to 2023, and projected CAGRs through 2028
- Estimate of the size and revenue prospects of the global market, along with a market share analysis by reprogramming method, generation method, application, product function, iPSC-derived cell type, species, end use, and region
- Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
- A Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
- Insights into iPSC research activity, emerging technologies, clinical trials and pipeline products
- Patent activity and analysis of recent patent grants/publications
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
- Analysis of the industry structure, including company market shares, strategic alliances, M&A activity and a venture funding outlook
- Profiles of market leaders, including Fujifilm Cellular Dynamics (FCDI) Inc., Axol Bioscience Ltd., Merck KGaA, Thermo Fisher Scientific Inc., and Takara Bio Inc.
Report Scope
The scope of this study encompasses an investigation of the market. BCC Research analyzes this market based on application type, product function, generation of iPSC and types of iPSC derived cells and species. Application-based market segments include drug development and toxicity testing, academic research and regenerative medicine. Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis. iPSC-derived cell-type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells and other cell types. Other cell types include astrocytes, fibroblasts and hematopoietic progenitor cells. BCC Research determines the current market status in each segment, examines its impact on future needs and presents growth forecasts through 2028.
The report also provides a detailed analysis of the market’s drivers, restraints, challenges and opportunities. In addition, the report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios and recent developments. it also provides detailed information on this market, emerging technologies and new developments, regulatory landscape, patent analysis, pipeline analysis and investment outlook and deals.
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2023-2028 |
| Base year market size | $3.1 Billion |
| Market size forecast | $5.2 Billion |
| Growth rate | CAGR of 9.1% from 2023 to 2028 |
| Units considered | $ Millions |
| Segments covered | By Reprogramming Method, Generation Method, Application, Product Function, iPSC-Derived Cell Type, Species, End Use, and Region |
| Regions covered | The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW) |
| Key Market Drivers |
|
| Companies studied |
|
Report Highlights
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 through 2028.
Report Includes
- 34 data tables
- An overview of the global market for induced pluripotent stem cells (iPSCs)
- Analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by reprogramming method, method, application, derived tissue cell type, species, product function, end use, and geographic region
- Analysis of the market’s dynamics, including drivers, restraints and opportunities, and the regulatory environments impacting the market
- Assessment of R&D activity in the iPSC segment, as well as new developments and pipeline products
- Information on the latest research activities, emerging technologies, and clinical trials
- Market share analysis of the key companies and coverage of mergers & acquisitions, joint ventures, collaborations, and partnerships
- Profiles of the major players in the industry
Report Highlights
The global market for induced pluripotent stem cells should grow from $2.8 billion in 2021 to $4.4 billion by 2026, at compound annual growth rate (CAGR) of 9.3% for the period of 2021-2026.
Report Includes
- 43 tables
- An updated review of the global market for induced pluripotent stem cells (iPSC) within the industry
- Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Estimation of the market size and revenue forecast for the iPSCs market, and corresponding market share analysis by market segments such as application, reprogramming method, iPSCs generation method, product function and geography
- Highlights of emerging technology trends, market opportunities and deterrents estimating current and future demand of iPSC-related products and their derivatives for drug discovery
- Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances, or other advantages
- Discussion of market dynamics that impact the growth of the market for iPSCs, clinical applications, market regulations, industry structure, and penetration of technologies within the biotech industry
- Insight into the segmentation of iPSC products, including iPSC research and clinical products, along with application-based segments such as academic research, drug development and regenerative medicine as well as iPSC-related contract services
- Number of global (+ the U.S.) patents and patent applications on induced pluripotent stem cells, and corresponding iPSC scientific publications during the period of 2008-October 2019
- Competitive landscape of the key manufacturers and suppliers in the iPSC market, their competitive environment and major growth strategies within the global market
- Descriptive company profiles of leading industry players, including Applied Biological Materials Inc., Bristol-Myers Squibb, Corning Inc., Merck KGaA and Thermo Fisher Scientific
Report Highlights
The global induced pluripotent stem cells (iPSC) market should reach $3.8 billion by 2024 from $2.4 billion in 2019 at a compound annual growth rate (CAGR) of 9.2% for the forecast period of 2019 to 2024.
Report Includes
- 59 tables
- An overview of the global market for induced pluripotent stem cells
- Analyses of global market trends with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Information on induced pluripotent stem cell research products, including various assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes
- Complete understanding of the key technologies adopted for induced pluripotent stem cell research
- Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth
- Profiles of major players in the industry, including Applied StemCell Inc., BlueRock Therapeutics, Corning Life Sciences, EMD Millipore, Lonza Group Ltd., Promega Corp. and Thermo Fisher Scientific Inc.
Report Highlights
The global market for induced pluripotent stem cells (iPSCs) reached $2.1 billion in 2016. The market should reach $3.6 billion in 2021, increasing at a compound annual growth rate (CAGR) of 11.6% from 2016 through 2021.
Report Includes
- An overview of the global market for induced pluripotent stem cells.
- Analyses of global market trends with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Information on induced pluripotent stem cell research products, defined as all research tools including but not limited to: induced pluripotent stem cells and various differentiated cells derived from induced pluripotent stem cells; various related assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes, and many others that can be applied for the specific purpose of executing induced pluripotent stem cell research.
- Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth.
- Profiles of major players in the industry.
Report Highlights
The global market for induced pluripotent stem cells (iPSCs) was estimated to total $853 million in 2012, and close to $1.2 billion in 2013, averaging 40% growth. The market is expected to reach $2.9 billion in 2018, an estimated compound annual growth rate (CAGR) of 19.7% for the five-year period 2013 to 2018.
Report Includes
- An overview of the global market for induced pluripotent stem cells.
- Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
- Information on induced pluripotent stem cell research products, defined as all research tools including but not limited to: induced pluripotent stem cells and various differentiated cells derived from induced pluripotent stem cells, various related assays and kits, culture media and medium components such as serum, growth factors and inhibitors, antibodies, enzymes, and many others that can be applied for the specific purpose of executing induced pluripotent stem cell research.
- Discussion of important manufacturers, technologies, and factors influencing market demand such as the driving forces and limiting factors of induced pluripotent stem cell market growth.